Cancer Vaccine Candidae - Celldex Presents Results From Phase 1 Studies Of CDX-1307 With GM-CSF

Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced initial results from multi-center Phase 1 clinical trials of its cancer vaccine candidate, CDX-1307, combined with GM-CSF, at the International Society for the Biologic Therapy of Cancer (iSBTc) annual meeting in San Diego. These data provide the basis for the ongoing assessment of CDX-1307 combined with more potent adjuvants with data expected in the first half of 2009.

More: continued here

Filed under: Cancer on November 3rd, 2008